Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

1988 • 1,634 citations

Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)

1989 • 1,199 citations

Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy

1995 • 637 citations

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

1993 • 606 citations

Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

1995 • 539 citations

Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)

1995 • 524 citations

The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter

1996 • 494 citations

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

1992 • 429 citations

A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

1998 • 395 citations

Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive Subjects

1992 • 369 citations

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1993 • 320 citations

Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase

1996 • 306 citations

Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

1995 • 259 citations

Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies

1996 • 214 citations

Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing

1993 • 200 citations

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients

1996 • 183 citations

Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

1994 • 158 citations

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

1993 • 153 citations

Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment

1995 • 141 citations

A Mutation in Human Immunodeficiency Virus Reverse Transcriptase and Decline in CD4 Lymphocyte Numbers in Long-Term Zidovudine Recipients

1993 • 129 citations

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

1996 • 118 citations

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1991 • 111 citations

An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine

1996 • 110 citations

Lamivudine‐Resistant Human Immunodeficiency Virus Type 1 Variants (184V) Require Multiple Amino Acid Changes to Become Co‐Resistant to Zidovudine In Vivo

1997 • 110 citations

Development of HIV-1 resistance to (−)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex

1995 • 109 citations

HIV-1 sensitivity to zidovudine and clinical outcome in children

1992 • 108 citations

In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome

1992 • 91 citations

Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial

1993 • 68 citations

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

1994 • 64 citations

Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments

1997 • 63 citations

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

1996 • 53 citations

Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype

1996 • 22 citations

Provirus Load Changes in Untreated and Zidovudine-Treated Human Immunodeficiency Virus Type I-Infected Patients

1994 • 17 citations

HIV-1 Reverse Transcriptase Codon 215 Mutation and Clinical Outcome in Children Treated with Zidovudine

1994 • 16 citations

Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients

1995 • 11 citations

Correlation of Clinical Progression in Human Immunodeficiency Virus-Infected Children with In Vitro Zidovudine Resistance Measured by a Direct Quantitative Peripheral Blood Lymphocyte Assay

1995 • 11 citations

Deleted Work

1955 • 0 citations